Clinical Trials Logo

Autosomal Dominant Optic Atrophy clinical trials

View clinical trials related to Autosomal Dominant Optic Atrophy.

Filter by:
  • None
  • Page 1

NCT ID: NCT06461286 Not yet recruiting - Clinical trials for Autosomal Dominant Optic Atrophy

SAD of IVT PYC-001 in OPA1 Mutation-Associated Autosomal Dominant Optic Atrophy (Sundew)

Start date: July 2024
Phase: Phase 1
Study type: Interventional

A First-in-Human multi-centre, prospective, Phase1a, Single Ascending Dose (SAD) interventional study of PYC-001 in participants with confirmed OPA1 mutation (haploinsufficiency) associated ADOA.

NCT ID: NCT06140329 Recruiting - Clinical trials for Autosomal Dominant Optic Atrophy

Natural History of Autosomal Dominant Optic Atrophy (ADOA), Caused by OPA1 Mutation

Start date: February 28, 2024
Phase:
Study type: Observational

The purpose of this study is to characterize the disease progression of confirmed OPA1 mutation-associated autosomal dominant optic atrophy (ADOA) by evaluating the changes in ocular structural and functional outcomes.

NCT ID: NCT01793168 Recruiting - Clinical trials for Retinitis Pigmentosa

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

CoRDS
Start date: July 2010
Phase:
Study type: Observational [Patient Registry]

CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, international patient registry for all rare diseases. This program allows patients and researchers to connect as easily as possible to help advance treatments and cures for rare diseases. The CoRDS team works with patient advocacy groups, individuals and researchers to help in the advancement of research in over 7,000 rare diseases. The registry is free for patients to enroll and researchers to access. Visit sanfordresearch.org/CoRDS to enroll.